Kyowa Kirin International appoints Julie Dehaene-Puype as new regional president

UK—Kyowa Kirin International, a subsidiary of the Japan-based global specialty pharmaceutical company Kyowa Kirin Co., Ltd., has named Julie Dehaene-Puype as President for the International Region, effective from November 1, 2025.

She succeeds Jeremy Morgan, who has led the region since 2023.

Morgan will transition to an advisory role through the end of 2025, collaborating closely with Dehaene-Puype to ensure a smooth leadership transition.

With over 25 years of experience in the pharmaceutical industry, Julie Dehaene-Puype brings extensive expertise spanning general management, commercial operations, new product development, and regulatory affairs.

Her career includes senior roles at prominent global pharmaceutical companies such as Mundipharma, Takeda, Merck/MSD, and Schering-Plough.

In addition to her operational roles, she serves as a Non-Executive Director on the board of Lytix Biopharma.

Tomohiro Sudo, Chief International Business Officer of Kyowa Kirin, expressed enthusiasm about Dehaene-Puype’s appointment.

He highlighted her comprehensive experience in global biotech and pharma across a 25-year career, emphasizing that her expertise, combined with her passion and commitment to patient care, will contribute significantly to the company’s growth and vision toward 2030.

Abdul Mullick, Ph.D., President and COO of Kyowa Kirin, also thanked Jeremy Morgan for his strong leadership and dedication to employees and patients during his tenure.

Mullick praised Morgan for fostering a culture focused on community needs and successfully guiding the company through significant transformations.

Julie Dehaene-Puype expressed excitement about joining Kyowa Kirin, a company with a 76-year legacy of scientific innovation and partnership.

She highlighted the organization’s deep commitment to advancing care in rare diseases and oncology and noted the shared purpose she observed from her first days at the company: to bring smiles to patients.

She looks forward to collaborating with her new colleagues to deliver more for the patients who trust Kyowa Kirin.

Dehaene-Puype holds a PharmD, a Master’s degree in Pharmaceutical Regulatory Affairs, and a Master’s in Biological and Medical Sciences, all from the University of Lille, France.

 She has lived and worked in France, Belgium, Switzerland, and the US.

Currently residing in Switzerland, she will regularly work from Kyowa Kirin’s headquarters in Marlow, UK, and the company’s offices across the region.

This leadership change is part of wider structural adjustments within Kyowa Kirin.

Earlier in 2025, the company introduced a dual CEO-COO leadership model to support continued growth, appointing Abdul Mullick as President and COO to oversee global business operations.

Kyowa Kirin remains focused on providing innovative medicines that bring life-changing benefits, with ongoing efforts centered on rare diseases, oncology, bone and mineral disorders, and hematology.

The company’s leadership changes reflect its commitment to strengthening global operations and advancing its Vision 2030 strategy with dedicated and experienced professionals at the helm.

Sign up HERE to receive our email newsletters with the latest news and insights from Africa and beyond. Also, follow us on our WhatsApp channel for updates.